SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Sun Pharma Advanced Research declines on reporting net loss of Rs 9.40 crore in Q4

06 May 2015 Evaluate

Sun Pharma Advanced Research Company is currently trading at Rs 395.95, down by 17.80 points or 4.30% from its previous closing of Rs. 413.75 on the BSE.

The scrip opened at Rs. 405.20 and has touched a high and low of Rs. 417.35 and Rs. 395.80 respectively. So far 275737 shares were traded on the counter.

The BSE group 'A' stock of face value Rs 1 has touched a 52 week high of Rs 598.00 on 10-Mar-2015 and a 52 week low of Rs. 151.00 on 19-May-2014.

Last one week high and low of the scrip stood at Rs. 444.90 and Rs. 394.25 respectively. The current market cap of the company is Rs. 9506.05 crore.

The promoters holding in the company stood at 67.13% while Institutions and Non-Institutions held 6.99% and 25.88% respectively.

Sun Pharma Advanced Research Company has reported a net loss of Rs 9.40 crore for the quarter ended March 31, 2015 as compared to a net loss of Rs 2.51 crore for the same quarter in the previous year. Total income of the company  decreased by 4.60% at Rs 43.13 crore for quarter under review as compared to Rs 45.21 crore for the quarter ended March 31, 2014.

For the year ended March 31, 2015, the company has posted a net loss of Rs 39.52 crore as compared to a net profit of Rs 30.32 crore for the same period in the previous year. Total income of the company has decreased by 10.31% at Rs 158.77 crore for year under review as compared to Rs 177.03 crore for the period ended March 31, 2014.

Sun Pharma Adv. Res Share Price

147.90 -4.25 (-2.79%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Syngene Internation. 435.70
Indegene 486.80
CMS Info Systems 318.00
JITF Infralogistics 338.00
Sagility 42.95
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×